Anxiety in Huntington’s disease

Journal of Neuropsychiatry and Clinical Neurosciences

Volumn 27, Issue 4, 2015, Pages 262-271

  Dale, Maria ^a   van Duijn, Erik ^b  

^a Adult Mental Health Clinical Psychology Department   (United Kingdom)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

KETAMINE; OLANZAPINE; PRIDOPIDINE;

AGORAPHOBIA; ANXIETY DISORDER; ARTICLE; CAG REPEAT; COPING BEHAVIOR; DEPRESSION; DISEASE COURSE; EDUCATION PROGRAM; FOLSTEIN QUANTIFIED NEUROLOGIC EXAMINATION; HEALTH BELIEF; HOSPITAL ANXIETY AND DEPRESSION SCALE; HUMAN; HUNTINGTON CHOREA; ILLNESS BELIEF; IRRITABILITY; LOCOMOTION; MIXED ANXIETY AND DEPRESSION; NEUROLOGIC DISEASE ASSESSMENT; PAIN; PANIC; PARTICIPANT EDUCATION PROGRAM; PREVALENCE; PRIORITY JOURNAL; PROBLEM BEHAVIORS ASSESSMENT FOR HUNTINGTON DISEASE; PROFILE OF MOOD STATES; QUALITY OF LIFE; SOCIAL PHOBIA; SUICIDAL IDEATION; SUICIDE; SYMPTOMATOLOGY; SYSTEMATIC REVIEW; UNIFIED HUNTINGTON DISEASE RATING SCALE; ADAPTIVE BEHAVIOR; ANXIETY; COMPLICATION; PSYCHOLOGY;

ADAPTATION, PSYCHOLOGICAL; ANXIETY; ANXIETY DISORDERS; DISEASE PROGRESSION; HUMANS; HUNTINGTON DISEASE; QUALITY OF LIFE;

EID: 84944744147     PISSN: 08950172     EISSN: 15457222     Source Type: Journal    
DOI: 10.1176/appi.neuropsych.14100265     Document Type: Article

References (58)

1. Walker FO: Huntington's disease. Lancet 2007; 369:218-228
2. Folstein SE: Huntington's disease: A disorder of families. Baltimore, MD, Johns Hopkins University Press, 1989
3. Duff K, Paulsen JS, Beglinger LJ, et al: Predict-HD Investigators of the Huntington Study Group: Psychiatric symptoms in Hunting-ton's disease before diagnosis: the predict-HD study. Biol Psychiatry 2007; 62:1341-1346
4. Marshall J, White K, Weaver M, et al: Specific psychiatric manifestations among preclinical Huntington disease mutation carriers. Arch Neurol 2007; 64:116-121
5. Paulsen JS, Langbehn DR, Stout JC, et al: Detection of Hunting-ton's disease decades before diagnosis: the Predict-HD study. J Neurol NeurosurgPsychiatry 2008;79:874-880
6. Craufurd D, Thompson JC, Snowden JS: Behavioral changes in Huntington disease. Neuropsychiatry Neuropsychol Behav Neurol 2001; 14:219-226
7. van Duijn E, Kingma EM, van der Mast RC: Psychopathology in verified Huntington's disease gene carriers. J Neuropsychiatry Clin Neurosci 2007; 19:441-448
8. Paulsen JS, Nehl C, Hoth KF, et al: Depression and stages of Hun-tington's disease. J Neuropsychiatry Clin Neurosci 2005; 17:496-502
9. Anderson KE, Gehl CR, Marder KS, et al: Huntington's Study Group: Comorbidities of obsessive and compulsive symptoms in Huntington's disease. J Nerv Ment Dis 2010; 198:334-338
10. Anderson KE, Louis ED, Stern Y, et al: Cognitive correlates of obsessive and compulsive symptoms in Huntington's disease. Am J Psychiatry 2001; 158:799-801
11. Huntington Study Group: Unified Huntington's Disease Rating Scale: reliability and consistency. Mov Disord 1996; 11:136-142
12. Murgod UA, Saleem Q, Anand A, et al: A clinical study of patients with genetically confirmed Huntington's disease from India. J Neurol Sci 2001; 190:73-78
13. Shoulson I, Fahn S: Huntington disease: clinical care and evaluation. Neurology 1979; 29:1-3
14. Witjes-Ane MN, Zwinderman AH, Tibben A, et al: Behavioural complaints in participants who underwent predictive testing for Huntington's disease. J Med Genet 2002; 39:857-862
15. Thompson JC, Harris J, Sollom AC, et al: Longitudinal evaluation of neuropsychiatric symptoms in Huntington's disease. J Neuro-psychiatry Clin Neurosci 2012; 24:53-60
16. Cummings JL, Mega M, Gray K, et al: The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994; 44:2308-2314
17. Kulisevsky J, Litvan I, Berthier ML, et al: Neuropsychiatric assessment of Gilles de la Tourette patients: comparative study with other hyperkinetic and hypokinetic movement disorders. Mov Disord 2001; 16:1098-1104
18. Paulsen JS, Ready RE, Hamilton JM, et al: Neuropsychiatric aspects of Huntington's disease. J Neurol Neurosurg Psychiatry 2001; 71:310-314
19. Zigmond AS, Snaith RP: The hospital anxiety and depression scale. Acta Psychiatr Scand 1983; 67:361-370
20. Kristjanson LJ, Aoun SM, Oldham L: Palliative care and support for people with neurodegenerative conditions and their carers. Int J Palliat Nurs 2006; 12:368-377
21. Arran N, Craufurd D, Simpson J: Illness perceptions, coping styles and psychological distress in adults with Huntington'sdisease. Psychol Health Med 2014; 19:169-179
22. Decruyenaere M, Evers-Kiebooms G, Boogaerts A, et al: Prediction of psychological functioning one year after the predictive test for Huntington's disease and impact of the test result on reproductive decision making. J Med Genet 1996; 33:737-743
23. Soliveri P, Monza D, Piacentini S, et al: Cognitive and psychiatric characterization of patients with Huntington's disease and their at-risk relatives. Neurol Sci 2002; 23(Suppl 2):S105-S106
24. Vassos E, Panas M, Kladi A, et al: Effect of CAG repeat length on psychiatric disorders in Huntington's disease. J Psychiatr Res 2008; 42:544-549
25. van Duijn E, Kingma EM, Timman R, et al: Cross-sectional study on prevalences of psychiatric disorders in mutation carriers of Huntington's disease compared with mutation-negative first- degree relatives. J Clin Psychiatry 2008; 69:1804-1810
26. Leroi I, O'Hearn E, Marsh L, et al: Psychopathology in patients with degenerative cerebellar diseases: a comparison to Hunting- ton's disease. Am J Psychiatry 2002; 159:1306-1314
27. Reedeker W, van der Mast RC, Giltay EJ, et al: Psychiatric disorders in Huntington's disease: A 2-year follow-up study. Psychosomatics 2012; 53:220-229
28. Berrios GE, Wagle AC, Markova IS, et al: Psychiatric symptoms and CAG repeats in neurologically asymptomatic Huntington's disease gene carriers. Psychiatry Res 2001; 102:217-225
29. Berrios GE, Wagle AC, Markova IS, et al: Psychiatric symptoms in neurologically asymptomatic Huntington's disease gene carriers: a comparison with gene negative at risk subjects. Acta Psychiatr Scand 2002; 105:224-230
30. Julien CL, Thompson JC, Wild S, et al: Psychiatric disorders in preclinical Huntington's disease. J Neurol Neurosurg Psychiatry 2007; 78:939-943
31. Shiwach RS, Norbury CG: A controlled psychiatric study of individuals at risk for Huntington's disease. Br J Psychiatry 1994; 165: 500-505
32. Zappacosta B, Monza D, Meoni C, et al: Psychiatric symptoms do not correlate with cognitive decline, motor symptoms, or CAG repeat length in Huntington's disease. Arch Neurol 1996; 53:493-497
33. Litvan I, Paulsen JS, Mega MS, et al: Neuropsychiatric assessment of patients with hyperkinetic and hypokinetic movement disorders. Arch Neurol 1998; 55:1313-1319
34. McCabe MP, Firth L, O'Connor E: Mood and quality of life among people with progressive neurological illness. Int J Clin Health Psychol 2009; 9:21-35
35. Marder K, Zhao H, Myers RH, et al: Huntington Study Group: Rate of functional decline in Huntington's disease. Neurology 2000; 54: 452-458
36. Nimmagadda SR, Agrawal N, Worrall-Davies A, et al: Determinants of irritability in Huntington's disease. Acta Neuropsychiatr 2011; 23:309-314
37. Levy ML, Cummings JL, Fairbanks LA, et al: Apathy is not depression. J Neuropsychiatry Clin Neurosci 1998; 10:314-319
38. Kingma EM, van Duijn E, Timman R, et al: Behavioural problems in Huntington's disease using the Problem Behaviours Assessment. Gen Hosp Psychiatry 2008; 30:155-161
39. Rickards H, De Souza J, van Walsem M, et al: European Huntington's Disease Network: Factor analysis of behavioural symptoms in Hun-tington's disease. J Neurol Neurosurg Psychiatry 2011; 82:411-412
40. Rickards H, De Souza J, Crooks J, et al: European Huntington's Disease Network: Discriminant analysis of Beck Depression Inventory and Hamilton Rating Scale for Depression in Huntington's disease. J Neuropsychiatry Clin Neurosci 2011; 23:399-402
41. Wetzel HH, Gehl CR, Dellefave-Castillo L, et al: Huntington Study Group: Suicidal ideation in Huntington disease: the role of comorbidity. Psychiatry Res 2011; 188:372-376
42. Fiedorowicz JG, Mills JA, Ruggle A, et al: PREDICT-HD Investigators of the Huntington Study Group: Suicidal behavior in prodromal Huntington disease. Neurodegener Dis 2011; 8:483-490
43. Hubers AA, van Duijn E, Roos R, et al: Suicidal ideation in a European Huntington's Disease Population. J Affect Disord 2013; 151: 248-258
44. Decruyenaere M, Evers-Kiebooms G, Boogaerts A, et al: Psychological functioning before predictive testing for Huntington'sdisease:the role of the parental disease, risk perception, and subjective proximity of the disease. J Med Genet 1999; 36:897-905
45. Decruyenaere M, Evers-Kiebooms G, Cloostermans T, et al: Psychological distress in the 5-year period after predictive testing for Huntington's disease. Eur J Hum Genet 2003; 11:30-38
46. Jankovic J, Beach J, Ashizawa T: Emotional and functional impact of DNA testing on patients with symptoms ofHuntington's disease. J Med Genet 1995; 32:516-518
47. A'Campo LE, Spliethoff-Kamminga NG, Roos RA: The Patient Education Program for Huntington's Disease (PEP-HD). J Hun- tingtons Dis 2012; 1:47-56
48. Squitieri F, Cannella M, Porcellini A, et al: Short-term effects of olanzapine in Huntington disease. Neuropsychiatry Neuropsychol Behav Neurol 2001; 14:69-72
49. Piira A, van Walsam MR, Mikalsen G, et al: Effects of a one year intensive multidisciplinary rehabilitation program for patients with Huntington's disease: a prospective intervention study. PLoS Curr 2013;5
50. Somers JM, Goldner EM, Waraich P, et al: Prevalence and incidence studies of anxiety disorders: a systematic review of the literature. Can J Psychiatry 2006; 51:100-113
51. van Duijn E, Giltay EJ, Zitman FG, et al: Measurement of psy-chopathology in Huntington's disease: the critical role of caregivers. J Nerv Ment Dis 2010; 198:329-333
52. Beesdo K, Pine DS, Lieb R, et al: Incidence and risk patterns of anxiety and depressive disorders and categorization of generalized anxiety disorder. Arch Gen Psychiatry 2010; 67:47-57
53. Silver A: Cognitive-behavioural therapy with a Huntington's gene positive patient. Patient Educ Couns 2003; 49:133-138
54. Frank S; Huntington Study Group/TETRA-HD Investigators: Tetrabenazine as anti-chorea therapy in Huntington disease: an open-label continuation study. BMC Neurol 2009; 9:62
55. Rosenberg NK, S0rensen SA, Christensen AL: Neuropsychological characteristics of Huntington's disease carriers: a double blind study. J Med Genet 1995; 32:600-604
56. Decruyenaere M, Evers-Kiebooms G, Boogaerts A, et al: Predictive testing for Huntington's disease: risk perception, reasons for testing and psychological profile of test applicants. Genet Couns 1995; 6:1-13
57. Murman DL, Giordani B, Mellow AM, et al: Cognitive, behavioral, and motor effects of the NMDA antagonist ketamine in Hunting-ton's disease. Neurology 1997; 49:153-161
58. Lundin A, Dietrichs E, Haghighi S, et al: Efficacy and safety of the dopaminergic stabilizer Pridopidine (ACR16) in patients with Huntington's disease. Clin Neuropharmacol 2010; 33:260264